Sputum examination for early detection of lung cancer

Journal of Clinical Pathology

Volumn 56, Issue 11, 2003, Pages 805-810

  Thunnissen, F B J M ^a  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER SCREENING; CELL NUCLEUS; DIAGNOSTIC ACCURACY; DNA DETERMINATION; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LUNG CANCER; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; QUALITY CONTROL; REVIEW; SPUTUM CYTODIAGNOSIS; SPUTUM EXAMINATION;

DNA, NEOPLASM; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; SPUTUM; TUMOR MARKERS, BIOLOGICAL;

EID: 0242408197     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.11.805     Document Type: Review

References (74)

1. Miller YE, Franklin WA. Molecular events in lung carcinogenesis. Hematol Oncol Clin North Am 1997;11:215-34.
2. Hirsch FR, Franklin WA, Gazdar AF, et al. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001;7:5-22.
3. Tockman MS. Advances in sputum analysis for screening and early detection of lung cancer. Cancer Control 2000;7:19-24.
4. Wiest JS, Franklin WA, Drabkin H, et al. Genetic markers for early detection of lung cancer and outcome measures for response to chemoprevention. J Cell Biochem Suppl 1997;28/29:64-73.
5. Sozzi G, Oggionni M, Alasio L, et al. Molecular changes track recurrence and progression of bronchial precancerous lesions. Lung Cancer 2002;37:267-70.
6. Wistuba II, Mao L, Gazdar AF. Smoking: molecular damage in bronchial epithelium. Oncogene 2002;21:7298-306.
7. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-7.
8. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 1970-1977. N Engl J Med 1979;300:381-5.
9. Boers JE, Velde GPMt, Thunnissen FBJM. P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Am Rev Respir Dis 1996;153:411-16.
10. Martin B, Verdebout JM, Mascaux C, et al. Expression of p53 in preneoplastic and early neoplastic bronchial lesions. Oncol Rep 2002;9:223-9.
11. Venmans BJ, van Boxem TJ, Smit EF, et al. Outcome of bronchial carcinoma in situ. Chest 2000;117:1572-6.
12. Bota S, Auliac JB, Paris C, et al. Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med 2001;164:1688-93.
13. Saccomanno G, Archer VE, Auerbach O, et al. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974;33:256-70.
14. Ng AB, Horak GC. Factors significant in the diagnostic accuracy of lung cytology in bronchial washing and sputum samples. II. Sputum samples. Acta Cytol 1983;27:397-402.
15. Field JK, Brambilla C, Caporaso N, et al. Consensus statements from the second international lung cancer molecular biomarkers workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol 2002;21:369-73.
16. Kennedy TC, Proudfoot SP, Piantadosi S, et al. Efficacy af two sputum collection techniques in patients with air flow obstruction. Acta Cytol 1999;43:630-6.
17. Agusti C, Xaubet A, Monton C, et al. Induced sputum in the diagnosis of peripheral lung cancer not visible endoscopically. Respir Med 2001;95:822-8.
18. Roby TJ, Swan GE, Sorensen KW, et al. Discriminant analysis of lower respiratory tract components associated with cigarette smoking, based on quantitative sputum cytology. Acta Cytol 1990;34:147-154.
19. Mehta AC, Marty JJ, Lee FY. Sputum cytology. Clin Chest Med 1993;14:69-85.
20. Schumann GB, Roby TJ, Swan GE, et al. Quantitative sputum cytologic findings in 109 nonsmokers. Am Rev Respir Dis 1989;139: 601-603.
21. Feng Z, Tian D, Lan Q, et al. A sensitive immunofluorescence assay far detection of p53 protein accumulation in sputum. Anticancer Res 1999;19:3847-52.
22. Johnston WW, Bossen EH. Ten years of respiratory cytopathology at Duke University Medical Center. II. The cytopathologic diagnosis of lung cancer during the years 1970 to 1974, with a comparison between cytopathology and histopathology in the typing of lung cancer. Acta Cytol 1981;25:499-505.
23. Sing A, Freudenberg N, Kortsik C, et al. Comparison of the sensitivity of sputum and brush cytology in the diagnosis of lung carcinomos. Acta Cytol 1997;41:399-408.
24. Risse EK, van't Hof MA, Vaoijs GP. Relationship between patient characteristics and the sputum cytologic diagnosis of lung cancer. Acta Cytol 1987;31:159-65.
25. Risse EK, van't Hof MA, Laurini RN, et al. Sputum cytology by the Saccamanno method in diagnosing lung malignancy. Diagn Cytopathol 1985;1:286-91.
26. Frost JK, Ball WC Jr, Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 1984;130:549-54.
27. Woolner LB, Fontana RS, Cortese DA, et al. Roentgenographically occult lung cancer: pathologic findings and frequency of multicentricity during a 10-year period. Mayo Clin Proc 1984;59:453-66.
28. Sobue T, Moriyama N, Kaneko M, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002;20:911-20.
29. Dobray GS. The evaluation of cytology in the early diagnosis of pulmonary carcinoma. Acta Cytol 1970;14:95-103.
30. Bechtel JJ, Kelley WR, Petty TL, et al. Outcome of 51 patients with roentgenographically occult lung cancer detected by sputum cytologic testing: a community hospital program. Arch Intern Med 1994;154:975-80.
31. Strauss GM, Gleason RE, Sugarbaker DJ. Chest X-ray screening improves outcome in lung cancer. A reappraisal of randomized trials on lung cancer screening. Chest 1995;107:270S-9S.
32. Shaw GL. Screening for lung cancer. In: Johnson BE, Johnson DH, eds. Lung Cancer. New York: Wiley-Liss, 1995:41-54.
33. Sanderson DR. Lung cancer screening. The Mayo study. Chest 1986;89:324s.
34. Kennedy TC, Proudfoot SP, Franklin WA, et al. Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res 1996;56:4673-8.
35. Kennedy TC, Miller Y, Prindiville S. Screening for lung cancer revisited and the role of sputum cytology and fluorescence bronchoscopy in a high-risk group. Chest 2000;117:72S-9S.
36. Greenberg SD, Hunter NR, Taylor GR, et al. Application of cell-image analysis to the diagnosis of cellular atypias in sputum: a review. Diagn Cytopathol 1986;2:168-74.
37. Thunnissen FB, Diegenbach PC, van-Hattum AH, et al. Further evaluation of quantitative nuclear image features for classification of lung carcinomas. Pathol Res Pract 1992;188:531-5.
38. Petty TL, Tockman MS, Palcic B. Diagnosis of roentgenographically occult lung cancer by sputum cytology. Clin Chest Med 2002;23:59-64.
39. Payne PW, Sebo TJ, Doudkine A, et al. Sputum screening by quantitative microscopy: a reexamination of a portion of the National Cancer Institute cooperative early lung cancer study. Mayo Clin Proc 1997;72:697-704.
40. Palcic B, Garner DM, Beveridge J, et al. Increase of sensitivity of sputum cytology using high-resolution image cytometry: field study results. Cytometry 2002;50:168-76.
41. Marek W, Kotschy-Lang N, Muti A, et al. Can semi-automated image cytometry on induced sputum become a screening tool for lung cancer? Evaluation of quantitative semi-automated sputum cytometry on radon-and uranium-exposed workers. Eur Respir J 2001;18:942-50.
42. Qiao YL, Tockman MS, Li L, et al. A case-cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in China. Cancer Epidemiol Biomarkers Prev 1997;6:893-900.
43. Tockman MS, Erozan YS, Gupta P, et al. The early detection of second primary lung cancers by sputum immunostaining. LCEWDG investigators. Lung cancer early detection group. Chest 1994;106:385S-390S.
44. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 1997;3: 2237-46.
45. Sueoka E, Gota Y, Sueaka N, et al. Heterogeneous nuclear ribonucleoprotein B1 as a new marker of early detection for human lung cancers. Cancer Res 1999;59:1404-7.
46. Sueoka E, Sueoka N, Goto Y, et al. Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res 2001;61:1896-902.
47. Anderson M, Sladon S, Michels R, et al. Examination of p53 alterations and cytokeratin expression in sputa collected from patients prior ta histological diagnosis of squamous cell carcinoma. J Cell Biochem Suppl 1996;25:185-90.
48. Steven FS, Payne PW, Palcic B, et al. Sputum cells from lung tumour patients carry a cell surface marker not found in normal sputum. Anticancer Res 1998;18:2855-8.
49. Steven FS, Katsumi T, Payne PW, et al. Evidence for the induction of a tumour associated cell surface protease on cytologically normal epithelial cells present in the sputum of patients possessing lung tumours. Anticancer Res 1999;19:3491-3.
50. Huang MM, Arnheim N, Goodman MF. Extension of base mispairs by Taq DNA polymerase: implications for single nucleotide discrimination in PCR. Nucleic Acids Res 1992;20:4567-73.
51. Cline J, Braman JC, Hogrefe HH. PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res 1996;24:3546-51.
52. Rhodes CH, Honsinger C, Porter DM, et al. Analysis of the allele-specific PCR method for the detection of neoplastic disease. Diagn Mol Pathol 1997;6:49-57.
53. Mao L, Hruban RH, Bayle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994;54:1634-7.
54. Shiono S, Omoe K, Enda A. K-ras gene mutation in sputum samples containing atypical cells and adenocarcinoma cells in the lung. Carcinogenesis 1996;17:1683-6.
55. Yakubovskaya MS, Spiegelman V, Luo FC, et al. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 1995;63:810-14.
56. Nakajima E, Hirano T, Konaka C, et al. K-ras mutation in sputum of primary lung cancer patients does not always reflect that of cancerous cells. Int J Oncol 2001;18:105-10.
57. Behn M, Thiede C, Neubauer A, et al. Facilitated detection of oncogene mutations from exfoliated tissue material by a PNA-mediated "enriched PCR" protocol. J Pathol 2000;190:69-75.
58. Kersting M, Friedl C, Kraus A, et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000;18:3221-9.
59. Somers VAMC, Pietersen AM, Theunissen PHMH, et al. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by Point-EXACCT. J Clin Oncol 1998;16:3061-3068.
60. Somers VAMC, Leimbach DA, Theunissen PHMH, et al. Validation of the Point-EXACCT method in non-small cell lung carcinomas. Clin Chem 1998;44:1404-9.
61. Somers VA, Thunnissen FB. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. Methods Mol Med 2003;75:305-23.
62. Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques 2002;33:632, 634, 636-49.
63. Tsou JA, Hagen JA, Carpenter CL, et al. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002;21:5450-61.
64. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-6.
65. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7.
66. Gilliland FD, Harms HJ, Crowell RE, et al. Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum. Cancer Res 2002;62:2248-52.
67. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
68. Chen JT, Chen YC, Wang YC, et al. Alterations of the p16(ink4a) gene in resected nonsmall cell lung tumours and exfoliated cells within sputum. Int J Cancer 2002;98:724-31.
69. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 2001;29:E65-5.
70. Chen JT, Ho WL, Cheng YW, et al. Detection of p53 mutations in sputum smears precedes diagnosis of non-small cell lung carcinoma. Anticancer Res 2000;20:2687-90.
71. Miozzo M, Sozzi G, Musso K, et al. Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res 1996;56: 2285-8.
72. Nia AB, Maas LM, Van Breda SG, et al. Applicability of induced sputum for molecular dosimetry of exposure to inhalatory carcinogens: 32P-postlabeling of lipophilic DNA adducts in smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev 2000;9:367-72.
73. Lacroix J, Becker HD, Woerner SM, et al. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR. Int J Cancer 2001;92:1-8.
74. Thunnissen FB, Ellis IO, Jutting U, et al. Interlaboratory comparison of DNA image analysis. Management group report of internal quality assurance programme in the CAAC breast cancer project. Zentralbl Pathol 1994;139:443-7.